4DMT Received the US FDA’s RMAT Designation for 4D-150 to Treat Wet Age-Related Macular Degeneration
Shots:
- The designation was granted following the results from the P-I (PRISM) clinical trial evaluating the safety & tolerability of 4D-150 in patients with Wet AMD. Earlier in Oct 2023, 4D-150 received the PRIME designation by the EMA
- The results depicted a significant safety, tolerability & clinical activity in evaluable patients along with the potential to address an unmet medical need to safely maintain long-term visual acuity outcomes while avoiding the need for repeated interval injections
- 4D-150 comprises an intravitreal vector, R100 & a transgene cassette that expresses both aflibercept & a VEGF-C inhibitory RNAi. The company is currently working with the US FDA & EMA on the P-III clinical plans for 4D-150 & expects to provide updates & P-II trial data by Feb 2024
Ref: 4D Molecular Therapeutics | Image: 4D Molecular Therapeutics
Related News:- 4D Molecular Therapeutics Receives the US FDA’s IND Clearance of 4D-150 for the Treatment of Diabetic Macular Edema
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
